Leveraging biospecimen resources for discovery or validation of markers for early cancer detection

Sheri D. Schully, Danielle M. Carrick, Leah E. Mechanic, Sudhir Srivastava, Garnet L. Anderson, John A. Baron, Christine D. Berg, Jennifer Cullen, Eleftherios P. Diamandis, V. Paul Doria-Rose, Katrina A B Goddard, Susan E. Hankinson, Lawrence H. Kushi, Eric B. Larson, Lisa M. McShane, Richard L. Schilsky, Steven Shak, Steven J. Skates, Nicole Urban, Barnett S. KramerMuin J. Khoury, David F. Ransohoff

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Validation of early detection cancer biomarkers has proven to be disappointing when initial promising claims have often not been reproducible in diagnostic samples or did not extend to prediagnostic samples. The previously reported lack of rigorous internal validity (systematic differences between compared groups) and external validity (lack of generalizability beyond compared groups) may be effectively addressed by utilizing blood specimens and data collected within well-conducted cohort studies. Cohort studies with prediagnostic specimens (eg, blood specimens collected prior to development of clinical symptoms) and clinical data have recently been used to assess the validity of some early detection biomarkers. With this background, the Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) held a joint workshop in August 2013. The goal was to advance early detection cancer research by considering how the infrastructure of cohort studies that already exist or are being developed might be leveraged to include appropriate blood specimens, including prediagnostic specimens, ideally collected at periodic intervals, along with clinical data about symptom status and cancer diagnosis. Three overarching recommendations emerged from the discussions: 1) facilitate sharing of existing specimens and data, 2) encourage collaboration among scientists developing biomarkers and those conducting observational cohort studies or managing healthcare systems with cohorts followed over time, and 3) conduct pilot projects that identify and address key logistic and feasibility issues regarding how appropriate specimens and clinical data might be collected at reasonable effort and cost within existing or future cohorts.

Original languageEnglish (US)
JournalJournal of the National Cancer Institute
Volume107
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Early Detection of Cancer
Cohort Studies
Biomarkers
Neoplasms
National Cancer Institute (U.S.)
Tumor Biomarkers
Observational Studies
Delivery of Health Care
Education
Costs and Cost Analysis
Research
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schully, S. D., Carrick, D. M., Mechanic, L. E., Srivastava, S., Anderson, G. L., Baron, J. A., ... Ransohoff, D. F. (2015). Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. Journal of the National Cancer Institute, 107(4). https://doi.org/10.1093/jnci/djv012

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. / Schully, Sheri D.; Carrick, Danielle M.; Mechanic, Leah E.; Srivastava, Sudhir; Anderson, Garnet L.; Baron, John A.; Berg, Christine D.; Cullen, Jennifer; Diamandis, Eleftherios P.; Doria-Rose, V. Paul; Goddard, Katrina A B; Hankinson, Susan E.; Kushi, Lawrence H.; Larson, Eric B.; McShane, Lisa M.; Schilsky, Richard L.; Shak, Steven; Skates, Steven J.; Urban, Nicole; Kramer, Barnett S.; Khoury, Muin J.; Ransohoff, David F.

In: Journal of the National Cancer Institute, Vol. 107, No. 4, 01.04.2015.

Research output: Contribution to journalArticle

Schully, SD, Carrick, DM, Mechanic, LE, Srivastava, S, Anderson, GL, Baron, JA, Berg, CD, Cullen, J, Diamandis, EP, Doria-Rose, VP, Goddard, KAB, Hankinson, SE, Kushi, LH, Larson, EB, McShane, LM, Schilsky, RL, Shak, S, Skates, SJ, Urban, N, Kramer, BS, Khoury, MJ & Ransohoff, DF 2015, 'Leveraging biospecimen resources for discovery or validation of markers for early cancer detection', Journal of the National Cancer Institute, vol. 107, no. 4. https://doi.org/10.1093/jnci/djv012
Schully, Sheri D. ; Carrick, Danielle M. ; Mechanic, Leah E. ; Srivastava, Sudhir ; Anderson, Garnet L. ; Baron, John A. ; Berg, Christine D. ; Cullen, Jennifer ; Diamandis, Eleftherios P. ; Doria-Rose, V. Paul ; Goddard, Katrina A B ; Hankinson, Susan E. ; Kushi, Lawrence H. ; Larson, Eric B. ; McShane, Lisa M. ; Schilsky, Richard L. ; Shak, Steven ; Skates, Steven J. ; Urban, Nicole ; Kramer, Barnett S. ; Khoury, Muin J. ; Ransohoff, David F. / Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. In: Journal of the National Cancer Institute. 2015 ; Vol. 107, No. 4.
@article{773c64728de9423481d1db279ba40d61,
title = "Leveraging biospecimen resources for discovery or validation of markers for early cancer detection",
abstract = "Validation of early detection cancer biomarkers has proven to be disappointing when initial promising claims have often not been reproducible in diagnostic samples or did not extend to prediagnostic samples. The previously reported lack of rigorous internal validity (systematic differences between compared groups) and external validity (lack of generalizability beyond compared groups) may be effectively addressed by utilizing blood specimens and data collected within well-conducted cohort studies. Cohort studies with prediagnostic specimens (eg, blood specimens collected prior to development of clinical symptoms) and clinical data have recently been used to assess the validity of some early detection biomarkers. With this background, the Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) held a joint workshop in August 2013. The goal was to advance early detection cancer research by considering how the infrastructure of cohort studies that already exist or are being developed might be leveraged to include appropriate blood specimens, including prediagnostic specimens, ideally collected at periodic intervals, along with clinical data about symptom status and cancer diagnosis. Three overarching recommendations emerged from the discussions: 1) facilitate sharing of existing specimens and data, 2) encourage collaboration among scientists developing biomarkers and those conducting observational cohort studies or managing healthcare systems with cohorts followed over time, and 3) conduct pilot projects that identify and address key logistic and feasibility issues regarding how appropriate specimens and clinical data might be collected at reasonable effort and cost within existing or future cohorts.",
author = "Schully, {Sheri D.} and Carrick, {Danielle M.} and Mechanic, {Leah E.} and Sudhir Srivastava and Anderson, {Garnet L.} and Baron, {John A.} and Berg, {Christine D.} and Jennifer Cullen and Diamandis, {Eleftherios P.} and Doria-Rose, {V. Paul} and Goddard, {Katrina A B} and Hankinson, {Susan E.} and Kushi, {Lawrence H.} and Larson, {Eric B.} and McShane, {Lisa M.} and Schilsky, {Richard L.} and Steven Shak and Skates, {Steven J.} and Nicole Urban and Kramer, {Barnett S.} and Khoury, {Muin J.} and Ransohoff, {David F.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1093/jnci/djv012",
language = "English (US)",
volume = "107",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Leveraging biospecimen resources for discovery or validation of markers for early cancer detection

AU - Schully, Sheri D.

AU - Carrick, Danielle M.

AU - Mechanic, Leah E.

AU - Srivastava, Sudhir

AU - Anderson, Garnet L.

AU - Baron, John A.

AU - Berg, Christine D.

AU - Cullen, Jennifer

AU - Diamandis, Eleftherios P.

AU - Doria-Rose, V. Paul

AU - Goddard, Katrina A B

AU - Hankinson, Susan E.

AU - Kushi, Lawrence H.

AU - Larson, Eric B.

AU - McShane, Lisa M.

AU - Schilsky, Richard L.

AU - Shak, Steven

AU - Skates, Steven J.

AU - Urban, Nicole

AU - Kramer, Barnett S.

AU - Khoury, Muin J.

AU - Ransohoff, David F.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Validation of early detection cancer biomarkers has proven to be disappointing when initial promising claims have often not been reproducible in diagnostic samples or did not extend to prediagnostic samples. The previously reported lack of rigorous internal validity (systematic differences between compared groups) and external validity (lack of generalizability beyond compared groups) may be effectively addressed by utilizing blood specimens and data collected within well-conducted cohort studies. Cohort studies with prediagnostic specimens (eg, blood specimens collected prior to development of clinical symptoms) and clinical data have recently been used to assess the validity of some early detection biomarkers. With this background, the Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) held a joint workshop in August 2013. The goal was to advance early detection cancer research by considering how the infrastructure of cohort studies that already exist or are being developed might be leveraged to include appropriate blood specimens, including prediagnostic specimens, ideally collected at periodic intervals, along with clinical data about symptom status and cancer diagnosis. Three overarching recommendations emerged from the discussions: 1) facilitate sharing of existing specimens and data, 2) encourage collaboration among scientists developing biomarkers and those conducting observational cohort studies or managing healthcare systems with cohorts followed over time, and 3) conduct pilot projects that identify and address key logistic and feasibility issues regarding how appropriate specimens and clinical data might be collected at reasonable effort and cost within existing or future cohorts.

AB - Validation of early detection cancer biomarkers has proven to be disappointing when initial promising claims have often not been reproducible in diagnostic samples or did not extend to prediagnostic samples. The previously reported lack of rigorous internal validity (systematic differences between compared groups) and external validity (lack of generalizability beyond compared groups) may be effectively addressed by utilizing blood specimens and data collected within well-conducted cohort studies. Cohort studies with prediagnostic specimens (eg, blood specimens collected prior to development of clinical symptoms) and clinical data have recently been used to assess the validity of some early detection biomarkers. With this background, the Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) held a joint workshop in August 2013. The goal was to advance early detection cancer research by considering how the infrastructure of cohort studies that already exist or are being developed might be leveraged to include appropriate blood specimens, including prediagnostic specimens, ideally collected at periodic intervals, along with clinical data about symptom status and cancer diagnosis. Three overarching recommendations emerged from the discussions: 1) facilitate sharing of existing specimens and data, 2) encourage collaboration among scientists developing biomarkers and those conducting observational cohort studies or managing healthcare systems with cohorts followed over time, and 3) conduct pilot projects that identify and address key logistic and feasibility issues regarding how appropriate specimens and clinical data might be collected at reasonable effort and cost within existing or future cohorts.

UR - http://www.scopus.com/inward/record.url?scp=84930718091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930718091&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv012

DO - 10.1093/jnci/djv012

M3 - Article

C2 - 25688116

AN - SCOPUS:84930718091

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -